Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

American Journal of Hematology

Volumn 92, Issue 1, 2017, Pages 37-41

  Polverelli, Nicola ^a   Breccia, Massimo ^b   Benevolo, Giulia ^c   Martino, Bruno ^d   Tieghi, Alessia ^e   Latagliata, Roberto ^b   Sabattini, Elena ^a   Riminucci, Mara ^b   Godio, Laura ^c   Catani, Lucia ^a   Nicolosi, Maura ^c   Perricone, Margherita ^a   Sollazzo, Daria ^a   Colafigli, Gioia ^b   Campana, Anna ^c   Merli, Francesco ^e   Vitolo, Umberto ^c   Alimena, Giuliana ^b   Martinelli, Giovanni ^a   Lewis, Russell E ^f   Vianelli, Nicola ^a   Cavo, Michele ^a   Palandri, Francesca ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PYRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOODSTREAM INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGUS CANDIDIASIS; FATALITY; FEMALE; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; GYNECOLOGIC INFECTION; HUMAN; INFECTION RATE; INFECTION RISK; INFECTIOUS COMPLICATION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELOFIBROSIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SKIN INFECTION; SPLEEN SIZE; SPLENOMEGALY; THRUSH; TREATMENT OUTCOME; URINARY TRACT INFECTION; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNICABLE DISEASES; COMPLICATION; GENETICS; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PRIMARY MYELOFIBROSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMMUNICABLE DISEASES; FEMALE; HUMANS; INCIDENCE; JANUS KINASE 2; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PYRAZOLES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85001686837     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24572     Document Type: Article

References (38)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937–951.
2. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895–2901.
3. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703–1708.
4. Thiele J, Kvasnicka HM, Boeltken B. Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): A histochemical and morphometric study on sequential trephine biopsies. Leukemia Res 1999;23:983–985.
5. Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leukemia Res 2007;31:1503–1509.
6. Cervantes F, Hernandez-Boluda JC, Villamor N, et al. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol 2000;65:104–108.
7. Keohane C, Kordasti SY, Seidl T, et al. JAK inhibition reduces CD25 high CD27+FOXp3+ T regulatory cells and causes a silencing of T effector cells in patients with myeloproliferative neoplasms whilst promoting a TH17 phenotype. Blood 2013;122 Abstract n 4092.
8. Kundra A, Baptiste S, Chen C, Sindhu H, et al. Programmed cell death receptor (PD-1), PD-1 ligand (PD-L1) expression and myeloid derived suppressor cells (MDSC) in myeloid neoplasms implicate the mechanism of IMiD treatment of myelofibrosis. Blood 2013;122:2837.
9. Briard D, Brouty-Boye D, Giron-Michel J, et al. Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. Clin Immunol 2003;106:201–212.
10. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)−8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356–1363.
11. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
12. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798.
13. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: Results of a median 3-year follow-up of COMFORT-I. Haematologica 2015;100:479–488.
14. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047–4053.
15. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013;143:1478–1479.
16. Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep 2014. doi: 10.1136/bcr-2014-204950.
17. Palandri F, Polverelli N, Catani L, et al. Ruxolitinib-associated tuberculosis: A case of successful ruxolitinib rechallenge. Ann Hematol 2015;94:519–520.
18. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis? Blood 2013;122:3843–3844.
19. Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013;369:681–683.
20. Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013;369:197–198.
21. Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014;28:225–227.
22. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437–438.
23. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013;122:1395–1398.
24. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–332.
25. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821.
26. Jovanovic JV, Ivey A, Vannucchi AM, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 2013;27:2032–2039.
27. Palandri F, Latagliata R, Polverelli N, et al. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia 2015;29:1344–1349.
28. Shaffer LGSM, Campbell LJ. ISCN 2009: International System of Human Cytogenetic Nomenclature. Basel, Switzerland: Karger AG; 2009.
29. Hultcrantz M, Lund SH, Andersson TM, Björkholm M, et al. Myeloproliferative neoplasms and infections; a population-based study on 9,665 patients with myeloproliferative neoplasms diagnosed in Sweden 1987-2009. Haematologica 2015;100:p666.
30. Hultcrantz M, Wilkes SR, Kristinsson SY, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in sweden between 1973 and 2005: A population-based study. J Clin Oncol 2015;33:2288–2295.
31. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients. Haematologica 2015;100:107–113.
32. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392–397.
33. Tefferi A, Guglielmelli P, Finke C, Lasho TL, et al. Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis. Blood 2014;124:406.
34. Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: An AGIMM & IWG-MRT Project. Blood 2014;124:405.
35. Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest 2012;122:3888–3899.
36. Rosti V, Villani L, Riboni R, et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 2013;121:360–368.
37. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood 2012;120:1202–1209.
38. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015;100:1139–1145.